DBV Technologies SA – (DBVT) Stock Rating Upgraded by Societe Generale

DBV Technologies SA – (NDAQ:DBVT) was upgraded by equities research analysts at Societe Generale from a “hold” rating to a “buy” rating in a research note issued on Thursday.

DBV Technologies SA – (NDAQ:DBVT) opened at 34.88 on Thursday. The firm has a 50 day moving average of $35.33 and a 200-day moving average of $35.61. DBV Technologies SA – has a 52 week low of $27.02 and a 52 week high of $37.98. The company’s market capitalization is $1.60 billion.

Your IP Address:

About DBV Technologies SA –

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/dbv-technologies-sa-dbvt-stock-rating-upgraded-by-societe-generale/1708981.html

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *